Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DARENYSEARCA:DBVOTCMKTS:HIPHNASDAQ:MIRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAREDaré Bioscience$2.90$2.92$2.67▼$6.24$25.67M1.236,315 shs17,685 shsDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AHIPHAmerican Premium Mining$0.00$0.00▼$0.00$6.44M2.391.82 million shsN/AMIRAMIRA Pharmaceuticals$1.22-0.8%$1.08$0.51▼$5.01$20.81M1.932.19 million shs226,705 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAREDaré Bioscience0.00%+0.35%-3.65%-8.52%-39.58%DBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%HIPHAmerican Premium Mining0.00%0.00%0.00%0.00%0.00%MIRAMIRA Pharmaceuticals-0.81%-15.86%+32.46%+10.91%+33.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDAREDaré Bioscience1.3897 of 5 stars3.33.00.00.02.00.00.0DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AN/AN/AHIPHAmerican Premium MiningN/AN/AN/AN/AN/AN/AN/AN/AMIRAMIRA Pharmaceuticals1.4003 of 5 stars3.72.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAREDaré Bioscience 2.50Moderate Buy$12.00313.79% UpsideDBVInvesco DB G10 Currency Harvest Fund 0.00N/AN/AN/AHIPHAmerican Premium Mining 0.00N/AN/AN/AMIRAMIRA Pharmaceuticals 3.33Buy$14.001,047.54% UpsideCurrent Analyst Ratings BreakdownLatest HIPH, DARE, MIRA, and DBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025DAREDaré BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAREDaré Bioscience$25.91K990.58N/AN/A($0.61) per share-4.75DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AHIPHAmerican Premium Mining$70K0.00N/AN/AN/ANaNMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAREDaré Bioscience-$30.16M-$0.17N/AN/AN/A-191.65%N/A-18.98%8/11/2025 (Estimated)DBVInvesco DB G10 Currency Harvest FundN/AN/A0.00∞N/AN/AN/AN/AN/AHIPHAmerican Premium MiningN/AN/A0.00N/AN/AN/AN/AN/AN/AMIRAMIRA Pharmaceuticals-$11.98M-$0.51N/AN/AN/AN/A-337.44%-280.58%8/12/2025 (Estimated)Latest HIPH, DARE, MIRA, and DBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRAMIRA Pharmaceuticals-$0.15-$0.11+$0.04-$0.11N/AN/A5/13/2025Q1 2025DAREDaré Bioscience-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million3/31/2025Q4 2024DAREDaré Bioscience-$0.66-$0.64+$0.02-$0.64$1.00 million($0.06) million3/28/2025Q4 2024MIRAMIRA Pharmaceuticals-$0.29-$0.15+$0.14-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAREDaré BioscienceN/AN/AN/AN/AN/ADBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AHIPHAmerican Premium MiningN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAREDaré BioscienceN/A1.141.14DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AHIPHAmerican Premium MiningN/AN/AN/AMIRAMIRA PharmaceuticalsN/A6.116.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAREDaré Bioscience6.70%DBVInvesco DB G10 Currency Harvest Fund85.24%HIPHAmerican Premium MiningN/AMIRAMIRA Pharmaceuticals35.16%Insider OwnershipCompanyInsider OwnershipDAREDaré Bioscience4.00%DBVInvesco DB G10 Currency Harvest FundN/AHIPHAmerican Premium MiningN/AMIRAMIRA Pharmaceuticals6.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAREDaré Bioscience308.85 million8.35 millionNot OptionableDBVInvesco DB G10 Currency Harvest Fund801.00 millionN/ANot OptionableHIPHAmerican Premium Mining164.40 billionN/ANot OptionableMIRAMIRA Pharmaceuticals216.92 million15.46 millionNot OptionableHIPH, DARE, MIRA, and DBV HeadlinesRecent News About These CompaniesMIRA Pharmaceuticals Appoints New Chief Financial OfficerMay 21 at 5:55 PM | tipranks.comCritical Analysis: MIRA Pharmaceuticals (NASDAQ:MIRA) vs. Xeris Biopharma (NASDAQ:XERS)May 21 at 2:01 AM | americanbankingnews.comMIRA Releases Financials as Research ContinuesMay 15, 2025 | finance.yahoo.comMIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60MMay 9, 2025 | msn.comMIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment StrongMay 9, 2025 | msn.comMIRA Pharmaceuticals Acquires SKNY Pharmaceuticals for $60MMay 8, 2025 | tipranks.comMIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent ReviewMay 8, 2025 | accessnewswire.comMIRA Sets Up Success With Stellar Safety ResultsMay 7, 2025 | msn.comMIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked NeurotoxicityMay 6, 2025 | accessnewswire.comMira Pharmaceuticals reports in vitro drug release data for topical Ketamir-2April 25, 2025 | markets.businessinsider.comMIRA Pain Treatment Expands Market Size PotentialApril 23, 2025 | msn.comMIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track DesignationApril 23, 2025 | accessnewswire.comPharmaceutical Stock Jumps After Key Trial FindingsApril 17, 2025 | msn.comMira Pharmaceuticals announces results for Ketamir-2 in diabetic neuropathyApril 17, 2025 | markets.businessinsider.comMira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical TrialApril 17, 2025 | msn.comMIRA Continues Positive Testing RunApril 16, 2025 | msn.comEXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal StudyApril 16, 2025 | finance.yahoo.comMIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I CompletionApril 16, 2025 | accessnewswire.comMira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2April 2, 2025 | markets.businessinsider.comMIRA Enrolls Patients Amid Rapid ProgressApril 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To BuyBy Thomas Hughes | April 25, 2025View If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To BuyHIPH, DARE, MIRA, and DBV Company DescriptionsDaré Bioscience NASDAQ:DARE$2.90 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.87 -0.03 (-1.17%) As of 05/23/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Invesco DB G10 Currency Harvest Fund NYSEARCA:DBV$25.41 0.00 (0.00%) As of 03/10/2023PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.American Premium Mining OTCMKTS:HIPHAmerican Premium Mining Corporation focuses on supporting the blockchain ecosystem through proof-of-work and proof-of-stake mining of cryptocurrencies. The company was formerly known as American Premium Water Corporation and changed its name to American Premium Mining Corporation in May 2022. American Premium Mining Corporation is based in Playa Vista, California.MIRA Pharmaceuticals NASDAQ:MIRA$1.22 -0.01 (-0.81%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.20 -0.02 (-2.05%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
